Literature DB >> 23490599

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

K V S Hari Kumar1, Altamash Shaikh, Pitambar Prusty.   

Abstract

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23490599     DOI： 10.1016/j.diabres.2013.01.020

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  30 in total

Review 1.  Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus.

Authors:  Samie Sabet; Michelle E Condren; Angela F Boston; Lauren C Doak; Laura J Chalmers
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

Review 2.  Benefits of healthy adipose tissue in the treatment of diabetes.

Authors:  Subhadra C Gunawardana
Journal:  World J Diabetes       Date:  2014-08-15

Review 3.  Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.

Authors:  Xia Wang; Peilin Zheng; Gan Huang; Lin Yang; Zhiguang Zhou
Journal:  Clin Exp Med       Date:  2018-07-17       Impact factor: 3.984

Review 4.  Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective.

Authors:  Felix Aberer; Thomas R Pieber; Max L Eckstein; Harald Sourij; Othmar Moser
Journal:  Pharmaceutics       Date:  2022-05-31       Impact factor: 6.525

Review 5.  Bariatric Surgery in Type 1 Diabetes Mellitus: A Systematic Review.

Authors:  Kamal K Mahawar; Nimantha De Alwis; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

6.  Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.

Authors:  Lei Ding; Conny A Gysemans; Geert Stangé; Yves Heremans; Yixing Yuchi; Tatiana Takiishi; Hannelie Korf; Marie Chintinne; Richard D Carr; Harry Heimberg; Daniel Pipeleers; Chantal Mathieu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.

Authors:  Marcos M Lima-Martínez; Ernesto Guerra-Alcalá; Miguel Contreras; José Nastasi; Janelle A Noble; Constantin Polychronakos
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-09-01

Review 8.  Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.

Authors:  Nuria Vilarrasa; Patricia San Jose; Miguel Ángel Rubio; Albert Lecube
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-21       Impact factor: 3.168

Review 9.  Type 1 diabetes and cardiovascular disease.

Authors:  Oliver Schnell; Francesco Cappuccio; Stefano Genovese; Eberhard Standl; Paul Valensi; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2013-10-28       Impact factor: 9.951

10.  Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis.

Authors:  Hitomi Oda; Akihiro Mori; Peter Lee; Kaori Saeki; Toshiro Arai; Toshinori Sako
Journal:  J Vet Med Sci       Date:  2014-06-16       Impact factor: 1.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.